Antibodies News and Research

RSS

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

Countries with older populations have higher SARS-CoV-2 infections and deaths, says study

A new study examines some patterns revealed by a study of the factors operating in different regions and countries, to offer plausible hypotheses of these variations.

23 Feb 2021

Protective COVID-19 antibodies can transfer from mothers to babies in the womb

Antibodies that guard against COVID-19 can transfer from mothers to babies while in the womb, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers published in the American Journal of Obstetrics and Gynecology.

23 Feb 2021

Influenza A virus defective interfering particles against SARS-CoV-2

In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.

23 Feb 2021

In vivo imaging reveals how anti-CD20 antibodies guide the immune system to attack tumors

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use of the immune system to act and belong to a class of treatment called "immunotherapies." But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?

22 Feb 2021

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Seropositive individuals —people who received antibodies after COVID-19 infection — may be able to safely delay their second mRNA vaccine dose after all, according to the results of a new study.

22 Feb 2021

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Researchers at the New York University Grossman School of Medicine and Biohaven Pharmaceuticals found that the REGN10933 and REGN10987 combination was 9.1-fold less potent on the B.1.351 variant, which emerged in South Africa, and 16.2-fold less potent on mink cluster 5.

22 Feb 2021

Viral protein delivery system could facilitate COVID-19 research

Researchers in the United States have successfully delivered a critical structural protein found in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to a human cell line and tracked its localization deep within the cells.

22 Feb 2021

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

Today, the U.S. Food and Drug Administration issued guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Human monoclonal antibodies can act as a substitute for traditional antibiotics

In the course of a new and groundbreaking study, led by Dr, Natalia Freund and the doctoral candidate Avia Waston at the Sackler Medical Faculty, the research group succeeded in isolating monoclonal antibodies, which hindered the growth of tuberculosis germs in laboratory mice. The

22 Feb 2021

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.

22 Feb 2021

Some SARS-CoV-2 variants evade mRNA vaccine-induced humoral immune, says study

Understanding how variants escape vaccine-boosted immune function is necessary to neutralizing SARS-CoV-2. An international team of researchers from MIT and Harvard University in the USA analyzed Pfizer and Moderna vaccines' effectiveness in neutralizing spike proteins from 10 different strains of SARS-CoV-2.

22 Feb 2021

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

A research team from the University of Michigan Medical School, USA, developed a supplementary intranasal treatment to improve COVID-19 vaccine response and its effects on long-lasting immunity from other variants, such as the B.1.351 variant first found in South Africa.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Cissampelos pareira L. extracts demonstrate anti-SARS-CoV-2 activity in vitro

A team of scientists from India has recently investigated the antiviral potency of a traditional medicinal plant Cissampelos pareira L. in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The findings reveal that both whole-plant extracts and bioactive compounds can inhibit SARS-CoV-2 replication by modulating estrogen receptor 1 (ESR1) activity.

21 Feb 2021

Experts advocate for increased diversity in vaccine clinical trials

A team of scientific experts from across the U.S. and Puerto Rico are advocating for increased diversity in vaccine trials after publishing a new report that highlights a decade's worth of disparities.

20 Feb 2021